Grant of Options

Oxford Biomedica PLC
04 October 2023
 

Grant of options

 

London, UK - 04 October 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB) announces that on 04 October 2023 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

 

2023 LTIP and 2022 DBP Awards

 

Name of individual

Title

Number of shares subject to the 2022 DBP award

Number of shares subject to the 2023 LTIP award

Total shares over which options now held

Percentage of current issued share capital under option

Frank Mathias

Chief Executive Officer

-

323,178

323,178

0.334%

Stuart Paynter

Chief Financial Officer

63,869

142,469

538,211

0.556%

Sebastien Ribault

Chief Commercial Officer


66,903

66,903

0.069%

Mark Caswell

Site Head US Operations


74,172

74,172

0.077%

Lisa James

Chief People Officer

15,887

39,670

99,989

0.103%

James Miskin

Chief Technical Officer

32,189

56,262

215,035

0.222%

Kyriacos Mitrophanous

Chief Scientific Officer

35,256

57,906

277,856

0.287%

Madduri Ravi Rao

Chief Medical Officer

21,129

50,135

131,400

0.136%

Matthew Treagus

Chief Information Officer and Chief of Staff

32,468

54,433

143,648

0.148%

Natalie Walter

General Counsel

27,897

48,069

167,244

0.173%

 

Under the terms of the DBP plan, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.

 

In line with best practice and current investor guidance the quantum of the 2023 LTIP to Frank Mathias was scaled back from 200% of salary to 160% of salary and for Stuart Paynter the quantum of the 2023 LTIP was scaled back by 30% from 175% of salary to 122.5% of salary. The quantum of 2023 LTIP granted to other new members of SET was scaled back by 20%, all other members of the set had their awards scaled back by 30%

 

The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award). Details of the measures are included in the 2022 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.

 

The LTIP awards granted to Frank Mathias and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The 2023 awards granted to other participants will vest and be released following the assessment of the performance condition.

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Frank Mathias

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

323,178

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 323,178 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Stuart Paynter

2.

Reason for the notification

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

142,469

 

2022 DBP Award

 

Price

Volume

Nil

63,869

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 206,338 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Sebastien Ribault

2.

Reason for the notification

a)

Position/status

Chief Commercial Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

66,903

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 66,903 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Mark Caswell  

2.

Reason for the notification

a)

Position/status

Site Head of US Operations

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

74,172

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 74,172 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lisa James

2.

Reason for the notification

a)

Position/status

Chief People Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

39,670

 

2022 DBP Award

 

Price

Volume

Nil

15,887

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 55,557 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

56,262

 

2022 DBP Award

 

Price

Volume

Nil

32,189

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 88,451 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

57,906

 

2022 DBP Award

 

Price

Volume

Nil

35,256

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 93,162 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 



 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Madduri Rao

2.

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

 

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

50,135

 

2022 DBP Award

 

Price

Volume

Nil

21,129

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 71,264 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 



 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Matthew Treagus

2.

Reason for the notification

a)

Position/status

Chief Information Officer and Chief of Staff

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

54,433

 

2022 DBP Award

 

Price

Volume

Nil

32,468

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 86,901 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Natalie Walter

2.

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2023 LTIP Award

 

Price

Volume

Nil

48,069

 

2022 DBP Award

 

Price

Volume

Nil

27,897

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 75,966 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-10-04

f)

Place of the transaction

Outside of trading venue

 



 

 

-Ends-

 

For further information, please contact:


 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings